Vyome Holdings (HIND) Non Operating Interest Expenses (2024 - 2026)
Vyome Holdings (HIND) posted Non Operating Interest Expenses of $3325.0 for Q2 2026, up 16.87% on a QoQ basis from $2845.0 in Q1 2026, and down 94.08% year-over-year from $56139.0 in Q2 2025.
Analysis
Vyome Holdings (HIND) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends
Vyome Holdings has reported Non Operating Interest Expenses for 3 years, with the latest figure at $3325.0 in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses fell 94.08% year-over-year to $3325.0 in Q2 2026; TTM through Jun 2026 was $41718.0, a 80.1% decrease from a year earlier, with the FY2025 full-year figure at $146641.0, down 28.82% from the prior year.
- Non Operating Interest Expenses was $3325.0 for Q2 2026 at Vyome Holdings, up from $2845.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $56139.0 in Q2 2025, with the low at $2845.0 in Q1 2026.
- Average Non Operating Interest Expenses over 3 years is $31416.0, with a median of $35673.0 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses slumped 44.03% in 2025, then slumped 94.82% in 2026.
- Over 3 years, Non Operating Interest Expenses stood at $52775.0 in 2024, then sank by 81.16% to $9944.0 in 2025, then slumped by 66.56% to $3325.0 in 2026.
- The last three Non Operating Interest Expenses figures came in at $3325.0 (Q2 2026), $2845.0 (Q1 2026), and $9944.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | 3,325.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,325.00 |
| Mar 31, 2026 | 2,845.00 |
| Dec 31, 2025 | 9,944.00 |
| Sep 30, 2025 | 25,604.00 |
| Jun 30, 2025 | 56,139.00 |
| Mar 31, 2025 | 54,954.00 |
| Dec 31, 2024 | 52,775.00 |
| Sep 30, 2024 | 45,742.00 |